IL262961A - Therapeutic uses of a c-raf inhibitor - Google Patents

Therapeutic uses of a c-raf inhibitor

Info

Publication number
IL262961A
IL262961A IL262961A IL26296118A IL262961A IL 262961 A IL262961 A IL 262961A IL 262961 A IL262961 A IL 262961A IL 26296118 A IL26296118 A IL 26296118A IL 262961 A IL262961 A IL 262961A
Authority
IL
Israel
Prior art keywords
therapeutic uses
raf inhibitor
raf
inhibitor
therapeutic
Prior art date
Application number
IL262961A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL262961A publication Critical patent/IL262961A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL262961A 2016-06-10 2018-11-12 Therapeutic uses of a c-raf inhibitor IL262961A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348720P 2016-06-10 2016-06-10
PCT/IB2017/053405 WO2017212442A1 (en) 2016-06-10 2017-06-08 Therapeutic uses of a c-raf inhibitor

Publications (1)

Publication Number Publication Date
IL262961A true IL262961A (en) 2018-12-31

Family

ID=59215827

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262961A IL262961A (en) 2016-06-10 2018-11-12 Therapeutic uses of a c-raf inhibitor

Country Status (13)

Country Link
US (1) US20190175609A1 (OSRAM)
EP (1) EP3468595A1 (OSRAM)
JP (1) JP2019517549A (OSRAM)
KR (1) KR20190017767A (OSRAM)
CN (1) CN109310761A (OSRAM)
AU (1) AU2017279046B2 (OSRAM)
BR (1) BR112018075371A2 (OSRAM)
CA (1) CA3026876A1 (OSRAM)
CL (1) CL2018003530A1 (OSRAM)
IL (1) IL262961A (OSRAM)
MX (1) MX2018015353A (OSRAM)
RU (1) RU2018146886A (OSRAM)
WO (1) WO2017212442A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
JP7483741B2 (ja) 2019-03-08 2024-05-15 オーリス ヘルス インコーポレイテッド 医療システム用の傾斜機構及び用途
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
CN114746417B (zh) * 2019-12-06 2023-12-08 齐鲁制药有限公司 Pan-RAF激酶抑制剂的联芳基化合物
CN113912591B (zh) * 2020-07-08 2023-10-20 齐鲁制药有限公司 联芳基化合物
WO2022253334A1 (zh) * 2021-06-04 2022-12-08 南京明德新药研发有限公司 一种raf激酶抑制剂的晶型及其制备方法
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN118286440A (zh) * 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
AR101210A1 (es) * 2014-07-15 2016-11-30 Genentech Inc Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek

Also Published As

Publication number Publication date
JP2019517549A (ja) 2019-06-24
MX2018015353A (es) 2019-09-09
EP3468595A1 (en) 2019-04-17
CA3026876A1 (en) 2017-12-14
BR112018075371A2 (pt) 2019-03-19
CN109310761A (zh) 2019-02-05
RU2018146886A (ru) 2020-07-10
AU2017279046A1 (en) 2018-12-06
KR20190017767A (ko) 2019-02-20
US20190175609A1 (en) 2019-06-13
RU2018146886A3 (OSRAM) 2020-10-15
CL2018003530A1 (es) 2019-02-15
AU2017279046B2 (en) 2020-07-02
WO2017212442A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
IL262961A (en) Therapeutic uses of a c-raf inhibitor
IL248542B (en) Procedures for making jak1 inhibitor and novel forms thereof
IL250685A0 (en) Medicinal substance induces cytotoxicity
HUE056329T2 (hu) BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
IL254093A0 (en) Salts and processes for making a p13k inhibitor
PT3747472T (pt) Combinações terapêuticas de um inibidor de cd19 e um inibidor de btk
GB201410816D0 (en) Therapeutic agents
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
ZA201802256B (en) Compounds and therapeutic uses thereof
GB201509885D0 (en) Therapeutic agents
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
GB201502412D0 (en) Therapeutic use
GB201410817D0 (en) Therapeutic agents
GB201608797D0 (en) Therapeutic use
ZA201800558B (en) Combination therapy using acamprosate and d-cycloserine
GB201410815D0 (en) Therapeutic agents
LT3226888T (lt) Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
GB201509888D0 (en) Therapeutic agents
GB201506786D0 (en) Therapeutic use
HK40002691A (en) Therapeutic uses of a c-raf inhibitor
EP3164195A4 (en) Glutaminase inhibitor therapy
GB201512635D0 (en) Uses of therapeutic compounds
GB201421879D0 (en) Therapeutic agents
GB201421715D0 (en) Therapeutic agents
GB201409241D0 (en) Therapeutic agents